|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
|
28332824 |
2017 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent studies suggest that polymorphism in monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) might influence the risk and treatment of PD.
|
15355491 |
2004 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest that such compounds may be utilized for the development of new candidate MAO-B inhibitors for treatment of Parkinson's disease.
|
31146671 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Selegiline is an irreversible monoamine oxidase-B (MAO-B) inhibitor, and is widely used in the treatment of PD and major depression.
|
28515684 |
2017 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase B (MAO B) inhibitors, which inhibit dopamine decomposition by antagonizing MAO B activity, are approved and widely used for clinical treatment of Parkinson's disease (PD).
|
30004136 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our previous meta-analysis of PD genetic association studies, over a 30-year period yielded four genes (N-acetylcysteine 2, monoamine oxidase B, glutathione transferase, and mitochondrial tRNA), as their common variants were found to be associated with PD.
|
17868389 |
2007 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dopamine agonists, catechol-O-methyltransferase inhibitors and monoamine oxidase-B inhibitors are anti-parkinsonian (anti-PD) drugs that have been found to further improve the potency of l-dopa and prevent the onset of motor complications.
|
22093536 |
2011 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rasagiline mesylate is an irreversible MAO-B inhibitor which requires daily oral administration for treatment of Parkinson's disease due to its short half-life.
|
30877626 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
As another mechanism of clinical efficacy, MAO B inhibitors such as selegiline are speculated to have neuroprotective effects to prevent progress of PD.
|
17447416 |
2006 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
|
29198609 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B-specific inhibitors such as some of the quinazolinone compounds investigated here may act as leads for the design of therapies for neurodegenerative disorders such as Parkinson's disease.
|
31115748 |
2019 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using clinical data and DNA samples ascertained through the largest placebo-controlled clinical trial of the monoamine oxidase B inhibitor, rasagiline (ClinicalTrials.gov number, NCT00256204), we examined how polymorphisms in candidate genes associate with the clinical response to rasagiline in early Parkinson's disease.
|
27190009 |
2016 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results of our study further confirms that the dox-inducible astrocytic MAO-B transgenic mouse displays similar age-related behavioral and neuropathological features to other models of PD, and could serve as a useful tool to study PD pathophysiology and for the evaluation of therapeutic interventions.
|
23326597 |
2013 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The irreversible monoamine oxidase B (MAO B) inhibitor rasagiline has been described with multiple disease modifying effects in vitro on models of Parkinson's disease.
|
31421966 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we aimed to explore the antidepressant-like effects of propargyl MAO-B inhibitors, selegiline and rasagiline, in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a PD model, and to elucidate the mechanisms underlying these effects.
|
31427934 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results showed that PF promoted dopamine neuron survival in vivo due to the MAO-B inhibition, and the PI3K/Akt signaling pathway may have mediated the protection of PF against MPTP, suggesting that PF treatment might represent a neuroprotective treatment for PD.
|
28093210 |
2017 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, dual target ligands of the Adenosine A2A Receptor and Monoamine Oxidase B enzyme have been proposed as effective therapies for the treatment of Parkinson's disease.
|
28067172 |
2017 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The development of selective inhibitors of monoamine oxidase B (MAO-B) has been essential in treating Parkinson's disease.
|
31639490 |
2020 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The current pharmacological treatments for Parkinson's disease only offer symptomatic relief to the patients and are based on the administration of levodopa and catechol-O-methyltransferase or monoamine oxidase-B inhibitors (IMAO-B).
|
31336891 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
|
30386930 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
<b>:</b> Accumulative evidence indicated that the pathologically accumulated metal ions (iron species and Mn<sup>3+</sup>) and abnormally up-regulated monoamine oxidase B (MAOB) activity induced oxidation of endogenous dopamine (DA) can lead to mitochondria impairment, lysosome dysfunction, proteasome inhibition, and selective DA neuron vulnerability, which is implicated in the pathogenesis of Parkinson's disease (PD).
|
31426448 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B inhibitors are currently widely used as symptomatic therapeutics for PD and, although somewhat controversial, these drugs may also exhibit disease-modifying properties.
|
29713806 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conventional pharmacological treatment of PD is based on the replacement of dopamine using dopamine precursors (levodopa, L-DOPA, L-3,4 dihydroxyphenylalanine), dopamine agonists (amantadine, apomorphine) and MAO-B inhibitors (selegiline, rasagiline), which can be used alone or in combination with each other.
|
30214392 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, symptomatic effects of MAO-B inhibition for a limited amelioration of impaired motor behaviour and wearing-off phenomena in patients with Parkinson's disease are well proven, even when MAO-B inhibitors are only applied together with dopamine agonists.
|
29569037 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease.
|
9129714 |
1997 |